TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy confirmed advanced obstructing endobronchial non-small cell lung cancer~  * May have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma histology~* Ineligible for or refused surgical resection~* Local endobronchial recurrence after prior surgical resection, radiotherapy, or chemotherapy allowed~* No evidence of tumor encasement of major pulmonary vessels on CT scan of the chest~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2~* WBC ≥ 4,000/mm³~* Platelet count ≥ 100,000/mm³~* Prothrombin time \< 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 2.0 mg/dL~* Creatinine ≤ 2.0 mg/dL~* Alkaline phosphatase (hepatic) ≤ 3 times ULN~* SGOT ≤ 3 times ULN~* No contraindications for bronchoscopy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after the completion of study treatment~* Patients with underlying lung disease must be judged (by the principal investigator) able to withstand mucous/debris formation at the site of treatment~* Patients who cannot breathe due to complete upper airway obstruction and who need emergency treatment to open the airway are not eligible~* No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds~* No severe chronic obstructive pulmonary disease that, in the opinion of the investigator, would preclude multiple bronchoscopies~* No partial central airway obstruction from mucous/debris formation~* No high-grade upper airway obstruction of the trachea~PRIOR CONCURRENT THERAPY:~* Any type of prior therapy (e.g., chemotherapy or radiotherapy) for lung cancer allowed~* At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HPPH (Type: EXPERIMENTAL): Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Combining Observational and Physiologic Sedation Assessment Tools

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult~* admitted with a neurological or neurosurgical diagnosis~* intubated and on mechanical ventilatory support~* receiving continuous sedation with propofol~* Glasgow Coma Score \<12~Exclusion Criteria:~* bifrontal brain injury~* status epilepticus~* barbiturate coma therapy~* continuous benzodiazepine administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard-of-care (Type: ACTIVE_COMPARATOR): The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
- standard + BIS (Type: EXPERIMENTAL): Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent according to ICH/EU/GCP and national local laws~* Age 18 - 65 years~* Diagnosis of untreated Ph- ALL entering treatment including PEG-ASP in induction and consolidation~* ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself and not by pre-existing comorbidity, and is considered and/or documented to be reversible following the application of antileukemic therapy and appropriate supportive measures~Exclusion Criteria:~* Diagnosis of Burkitt's leukemia~* Down's syndrome~* Adults with Ph+ ALL~* Pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV)~* Severe liver disease with serum bilirubin \>3 mg/dL and/or ALT \>3 x upper normal limit (unless attributable to ALL)~* Kidney function impairment with serum creatinine \>2 mg/dL (unless attributable to ALL)~* Severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan~* Presence of serious, active, uncontrolled infections~* Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV positivity is detected after enrolment, the patient is put off study.~* Pregnancy~* Men and women should use effective contraception during treatment and for at least 6 months after Asparaginase discontinuation. As a precautionary measure, breast-feeding should be discontinued during treatment with Asparaginase and should not be restarted after discontinuation of Asparaginase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients on Oncospar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-reflux Control to Decrease Post Tonsillectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 7-17 years old~* Weight \>20 kg~* Scheduled to undergo a tonsillectomy (with or without adenoidectomy) in greater than four weeks.~* Health conditions (any of the following): Hypertrophic tonsils and adenoids, sleep disordered breathing, obstructive sleep apnea, chronic or recurrent tonsillitis, halitosis, dysphagia~* Must be able to swallow pills or tolerate taking the medication sprinkled on applesauce or other soft food.~Exclusion Criteria:~* Age \<7~* Weight \<20kg~* Patients declared by the parent not able to communicate pain level.~* Patients whose tonsillectomy is scheduled \<4 weeks from the preoperative assessment (The patient would not have time to complete the preoperative treatment) (An exception to this exclusion criteria will be for the control group)~* Patients with a mental illness. This will be determined by the patient's physician or the physician overseeing the care of the patient.~* Unable to swallow pills or tolerate sprinkling the medication on soft food.~* Pregnant patients~* Any patients already taking Proton Pump Inhibitor

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Omeprazole (Type: ACTIVE_COMPARATOR): Yes. Omeprazole (generic) will be used. Children \>20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain.
- Sugar pill (Type: PLACEBO_COMPARATOR): The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with oral, oropharyngeal, hypopharyngeal or laryngeal cancer having non-surgical treatment with chemoradiation, or radiation therapy alone, resulting in treatment associated dysphagia.~Exclusion Criteria:~* unable to adhere to assigned therapy program due to cognitive deficits~* surgical treatment for head and neck cancer~* unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional Therapy Only (Type: OTHER): Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion.
- Traditional Therapy with IOPI (Type: EXPERIMENTAL): Standard of care therapy plus the addition of the IOPI instrument

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* FEV1 between 20 and 60% predicted after having received 5 mg of albuterol and 0.5 mg of atrovent as nebulized standard of care therapy~* Male or female between the ages of 18 and 45~* Asthma diagnosed by a physician and present for at least 6 months~* oxygen saturation greater or equal to 90% on room air~* Non smoker or \< 10 pack-year history~* No other cause for wheezing/sob as determined by the treating physician~Exclusion Criteria:~* Clinical evidence or history of hepatic, renal, cardiovascular, GI, endocrine, metabolic or CNS disease which might interfere with the conduct of the study~* Acute respiratory failure or other significant pathology of the pulmonary system~* Female subjects who are pregnant or lactating~* Currently receiving therapy for a psychiatric disorder~* Subjects with a known sensitivity to formoterol (racemic or RR) or albuterol (racemic or lev)~* History of hospitalization for asthma within 2 months or treatment for acute asthma in an ED within 2 weeks of study entry~* Past or current use of disallowed medications~* Participation in an investigational study within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Arformoterol 3 doses (Type: EXPERIMENTAL): None
- Arformoterol 1 dose, placebo 2 doses (Type: EXPERIMENTAL): None
- Levalbuterol 3 doses (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Giant Cells Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient suffering from giant cells arteritis.~* Inclusion while discovery of symptoms, or during relapse.~Exclusion Criteria:~* Healthy volunteer~* Treatment with corticosteroid since more than 8 days for a patient suffering from giant cells arteritis, exept for patients under corticosteroid for a polymyalgia rheumatica.~* Other diseases than giant cells arteritis that could introduce an inflammatory symptom, especially a tumoral process in progress or a chronic inflammatory disease (any other one than giant cells arteritis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with giant gells arteritis (Type: OTHER): 50 patients with giant gells arteritis
- Control patients (Type: OTHER): 50 control patients : blood from French national blood service (EFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SMARTease Trial: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* history of one or more strokes;~* living in the community;~* subjective concerns about cognitive function;~* ability to give informed consent;~* fluent in written and spoken English.~Exclusion Criteria:~* unstable medical conditions or a co-morbid neurological disorder that could additionally impact cognitive or daily function, such as Parkinson's disease or Multiple Sclerosis;~* no available caregiver or significant other willing to participate in approximately one hour of telephone contact per week with coach and stroke survivor;~* current symptoms of severe depression (Geriatric Depression Scale\>20), global aphasia, or dementia (determined by baseline testing).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Training (Type: EXPERIMENTAL): telerehabilitation cognitive strategy training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* male or female patients~* ≥ 50 years of age;~* patients with compromised renal function, i.e. serum creatinine between 1.5 mg/dl and 3.0 mg/dl;~* patients scheduled for elective intervention;~* patients with an estimated intraoperative volume need of at least 1 l colloids;~* provision of voluntary informed consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations~Exclusion:~* patients of ASA-class \> III;~* patients with daily urine output \< 1 l;~* patients on haemodialysis;~* patients receiving HES during the last 48 hours before first infusion of the investigational products;~* patients suffering from coagulation disorders (i.e. PTT \> 60 sec);~* patients with a hemoglobin \< 9 g/dl;~* patients with known hypersensitivity to HES, albumin or any of the excipients;~* patients suffering from contraindications of the investigational products (i.e. hyperhydration state including pulmonary oedema, renal failure with oliguria or anuria, intracranial haemorrhage, hyperkalaemia, severe hypernatraemia or severe hyperchloraemia, severely impaired hepatic function, congestive heart failure);~* simultaneous participation in another clinical trial; emergencies;~* patients scheduled for brain surgery;~* patients incapable to give informed consent (e.g. patients with dementia, psychiatric diseases or suffering from conditions associated with lack of consciousness)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): HES 130/0.42 + Sterofundin ISO
- 2 (Type: ACTIVE_COMPARATOR): Albumin + NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DPP-4 Inhibition and TZD for DM Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Impaired glucose tolerance (IGT) by oral glucose tolerance test~Exclusion Criteria:~* History of diabetes mellitus~* History of congestive heart failure~* History of coronary artery disease or other macrovascular disease (stroke, peripheral vascular disease)~* History of liver disease (ALT or AST \>2.5 times the upper limit of normals)~* History of renal disease (serum creatinine \>1.5 mg/dl)~* History of severe osteoporosis (frequent fractures, failure on osteoporosis treatment)~* Current treatment with glucocorticoids~* History of immune disorder, including HIV~* Women of child-bearing age who are pregnant, desire to become pregnant, are breastfeeding, or who refuse to take the recommended birth control measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin + Pioglitazone PLACEBO (Type: EXPERIMENTAL): Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth
- Sitagliptin + Pioglitazone (Type: EXPERIMENTAL): Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth
- PLACEBO (Type: PLACEBO_COMPARATOR): Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of NonInvasive Blood Pressure in Neonates Through Adults and Special Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~Subjects will be included that:~1. Are aged \>29 days requiring clinically indicated non-emergent heart catheterization OR aged ≤29 days with placed or scheduled placement of an indwelling femoral, radial, or umbilical arterial monitoring line;~2. Have an upper limb (right OR left side) that fits a cuff size of the device (circumference ranging 3 cm to 40 cm) OR have a thigh (right OR left side) that fits a cuff size of the device (circumference ranging 38 to 50 cm);~3. Are expected to be able to provide blood pressure measurements using both IBP and NIBP;~4. Are able and willing to provide written informed consent or have a legally authorized representative willing to provide written informed consent with assent from minor patients, as required by IRB policy.~EXCLUSION CRITERIA~Subjects will be excluded that:~1. Have previously participated in this study (no subject may participate more than once).~2. Exhibit signs or symptoms or have a current diagnosis of peripheral vascular disease in either upper AND/OR lower limbs;~3. Have current, uncontrolled circulatory shock;~4. Exhibit injuries, deformities, intravenous lines, or other abnormalities that, in the opinion of the investigator, may prevent proper cuff application or functioning;~5. For women of child-bearing potential, are currently pregnant, suspected to be pregnant, or are currently lactating;~6. Have any condition that could interfere with the subjects ability to tolerate the procedure, including having a maximum of 4 fast flushes (adult, adolescent, or pediatric patients aged \>29 days) or 1 fast flush (neonates aged \<29 days);~7. If aged greater than 29 days but less than 12 years of age, have previously had any clinical or research procedure requiring general anesthesia in the last 3 month period;~8. If aged greater than 29 days but less than 12 years of age, are expected to require more than three (3) total hours of continuous general anesthesia for the scheduled procedure (including clinically necessary anesthesia and anticipated 25 minute extension for study purposes).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDM-SuperSTAT (Type: None): PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
- PSM-Datex-Ohmeda (Type: None): PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Telehealth Mindfulness for Back Pain in the Emergency Department

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older;~2. Presenting to the emergency department to address a chief complaint of an acute exacerbation of chronic low back pain;~3. Meets NIH-supported definition of chronic low back pain (e.g., pain greater than 3 months that has resulted in pain on at least half the days in the past 6 months); and~4. English-speaking due to feasibility of utilizing a telehealth mindfulness program developed in English~Exclusion Criteria:~1. Patients requiring hospitalization for a medical severe condition or comorbidity;~2. Patients with a severe psychiatric or behavioral diagnosis or presenting symptoms, including psychosis, delirium, active suicidal ideation, or who screen positive on the Columbia Suicide Screening;~3. Patients with a history of multiple substance use or abuse;~4. Patients involved in litigation related to the chronic pain condition; and~5. Patients who are unable to comply with the telehealth intervention (i.e., unable to provide stable home address or access telehealth link on a mobile device or computer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telehealth Mindfulness Program (Type: EXPERIMENTAL): Telehealth mindfulness sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues